Smith+Nephew announces the launch of the CENTRIO Platelet-Rich-Plasma System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. Smith+Nephew entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc., a commercial stage medical device company pioneering biodynamic therapies, to market the CENTRIO PRP System in the United States.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew Announces Updated Share Capital Structure
- Smith & Nephew Grants Share Awards to Executive
- Smith+Nephew Appoints Dr. Garheng Kong as Non-Executive Director
- Smith & Nephew Aligns Director Compensation with Shareholder Interests
- Smith & Nephew Director Acquires Shares as Part of Compensation Strategy